TrialThe AAPS journal2015

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Ahmed Abbas Suleiman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.